These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18989355)

  • 21. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
    Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
    J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M; Rabkin SD; Martuza RL
    Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.
    Israyelyan AH; Melancon JM; Lomax LG; Sehgal I; Leuschner C; Kearney MT; Chouljenko VN; Baghian A; Kousoulas KG
    Hum Gene Ther; 2007 May; 18(5):457-73. PubMed ID: 17536976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
    Lee CY; Rennie PS; Jia WW
    Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus.
    Carroll NM; Chiocca EA; Takahashi K; Tanabe KK
    Ann Surg; 1996 Sep; 224(3):323-9; discussion 329-30. PubMed ID: 8813260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.
    Grekova SP; Aprahamian M; Daeffler L; Leuchs B; Angelova A; Giese T; Galabov A; Heller A; Giese NA; Rommelaere J; Raykov Z
    Cancer Biol Ther; 2011 Nov; 12(10):888-95. PubMed ID: 22024742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraperitoneal chemotherapy with hydroxycamptothecin reduces peritoneal carcinomatosis: results of an experimental study.
    Li PC; Chen LD; Zheng F; Li Y
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):37-44. PubMed ID: 17665213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
    Wang J; Hu P; Zeng M; Rabkin SD; Liu R
    Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
    Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
    Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice.
    Takakuwa H; Goshima F; Nozawa N; Yoshikawa T; Kimata H; Nakao A; Nawa A; Kurata T; Sata T; Nishiyama Y
    Arch Virol; 2003 Apr; 148(4):813-25. PubMed ID: 12664303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of oncolytic reovirus against human gastric cancer with peritoneal metastasis in experimental animal model.
    Kawaguchi K; Etoh T; Suzuki K; Mitui MT; Nishizono A; Shiraishi N; Kitano S
    Int J Oncol; 2010 Dec; 37(6):1433-8. PubMed ID: 21042711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models.
    Shimoyama S; Goshima F; Teshigahara O; Kasuya H; Kodera Y; Nakao A; Nishiyama Y
    Hepatogastroenterology; 2007 Jun; 54(76):1038-42. PubMed ID: 17629034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.
    Varghese S; Rabkin SD; Nielsen GP; MacGarvey U; Liu R; Martuza RL
    Cancer Res; 2007 Oct; 67(19):9371-9. PubMed ID: 17909046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12.
    Wong RJ; Chan MK; Yu Z; Kim TH; Bhargava A; Stiles BM; Horsburgh BC; Shah JP; Ghossein RA; Singh B; Fong Y
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):251-259. PubMed ID: 14734477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
    Workenhe ST; Pol JG; Lichty BD; Cummings DT; Mossman KL
    Cancer Immunol Res; 2013 Nov; 1(5):309-19. PubMed ID: 24777969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.
    Goshima F; Esaki S; Luo C; Kamakura M; Kimura H; Nishiyama Y
    Int J Cancer; 2014 Jun; 134(12):2865-77. PubMed ID: 24265099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis.
    Lauer UM; Schell M; Beil J; Berchtold S; Koppenhöfer U; Glatzle J; Königsrainer A; Möhle R; Nann D; Fend F; Pfannenberg C; Bitzer M; Malek NP
    Clin Cancer Res; 2018 Sep; 24(18):4388-4398. PubMed ID: 29773661
    [No Abstract]   [Full Text] [Related]  

  • 39. Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application.
    Smith KD; Shao MY; Posner MC; Weichselbaum RR
    Future Oncol; 2007 Oct; 3(5):545-56. PubMed ID: 17927520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
    Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
    Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.